NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/02/2026
Back to search
Official data from USPTO
ONCOLOGY ONE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
07/02/2026
Classification
Registered
Trademark type
Combined
Nice classes
5
Filing date
03/17/2022
Registration date
02/20/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/20/2024
Last transaction
07/02/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
82
Owner location
AU
Examiner
GAINES, LEAH R
Law office
L60
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of two concentric unclosed circles around a closed circle design with the wording "ONCOLOGYONE" below.
Holders and representatives
Holders
Oncology One Pty Ltd
Representatives
Timothy J. Kelly TJ KELLY INTELLECTUAL PROPERTY LAW, PC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Biochemicals for pharmaceutical use for the treatment, prevention or diagnosis of cancer or diseases or disorders associated with cancer; chemicals for pharmaceutical use for the treatment of cancer or diseases or disorders associated with cancer; chemical preparations for medical purposes, namely, for cancer treatment, and prevention or diagnosis or the treatment of cancer, and prevention or diagnosis of diseases or disorders associated with cancer; chemical preparations for pharmaceutical purposes, namely, for cancer treatment, prevention or diagnosis or the treatment of cancer, and prevention or diagnosis of diseases or disorders associated with cancer; pharmaceutical preparations for the treatment of cancer and diseases and disorders associated with cancer; pharmaceutical products for the treatment of cancer and diseases and disorders associated with cancer
Publications
History of USPTO decisions and trademark events.
29 publications found
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
02/20/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
02/20/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/05/2023
PUBO
PUBLISHED FOR OPPOSITION
12/05/2023
GPNX
NOTIFICATION PROCESSED BY IB
12/03/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/15/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
11/15/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/15/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/30/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
10/30/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/30/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
10/30/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/30/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
10/23/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
10/04/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
10/04/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/26/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/26/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/26/2023
RFNP
REFUSAL PROCESSED BY IB
04/19/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/29/2023
RFRR
REFUSAL PROCESSED BY MPU
03/28/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/01/2023
CNRT
NON-FINAL ACTION WRITTEN
01/31/2023
DOCK
ASSIGNED TO EXAMINER
12/29/2022
MAFR
APPLICATION FILING RECEIPT MAILED
05/03/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/29/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
04/28/2022
Continuous trademark protection
Get notified about every new filing that threatens ONCOLOGY ONE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.